P2RX7 Gene

P2RX7 Gene

<table class="infobox infobox-gene">
<tr>
<th class="infobox-header" colspan="2">p2rx7</th>
</tr>
<tr>
<td class="label">Gene Symbol</td>
<td>P2RX7</td>
</tr>
<tr>
<td class="label">Full Name</td>
<td>Purinergic Receptor P2X Ligand-Gated Ion Channel 7</td>
</tr>
<tr>
<td class="label">Chromosome</td>
<td>12</td>
</tr>
<tr>
<td class="label">Genomic Location</td>
<td>12q24.31</td>
</tr>
<tr>
<td class="label">NCBI Gene ID</td>
<td>10278</td>
</tr>
<tr>
<td class="label">OMIM</td>
<td>601636</td>
</tr>
<tr>
<td class="label">Ensembl ID</td>
<td>ENSG00000088038</td>
</tr>
<tr>
<td class="label">UniProt ID</td>
<td>Q99572</td>
</tr>
<tr>
<td class="label">EC50 for ATP</td>
<td>~100-300 μM (much higher than other P2X receptors)</td>
</tr>
<tr>
<td class="label">Agonists</td>
<td>ATP, BzATP (more potent), dibutyryl-cAMP</td>
</tr>
<tr>
<td class="label">Antagonists</td>
<td>Brilliant Blue G, KN-62, A-438079, AZD9056</td>
</tr>
<tr>
<td class="label">Allosteric modulators</td>
<td>Zinc (potentiator), Copper (inhibitor), pH effects</td>
</tr>
<tr>
<td class="label">Ion selectivity</td>
<td>Non-selective for cations, impermeable to anions</td>
</tr>
<tr>
<td class="label">Compound</td>
<td>Company</td>
</tr>
<tr>
<td class="label">AZD9056</td>
<td>AstraZeneca</td>
</tr>
<tr>
<td class="label">GSK-1482160</td>
<td>GSK</td>
</tr>
<tr>
<td

P2RX7 Gene

<table class="infobox infobox-gene">
<tr>
<th class="infobox-header" colspan="2">p2rx7</th>
</tr>
<tr>
<td class="label">Gene Symbol</td>
<td>P2RX7</td>
</tr>
<tr>
<td class="label">Full Name</td>
<td>Purinergic Receptor P2X Ligand-Gated Ion Channel 7</td>
</tr>
<tr>
<td class="label">Chromosome</td>
<td>12</td>
</tr>
<tr>
<td class="label">Genomic Location</td>
<td>12q24.31</td>
</tr>
<tr>
<td class="label">NCBI Gene ID</td>
<td>10278</td>
</tr>
<tr>
<td class="label">OMIM</td>
<td>601636</td>
</tr>
<tr>
<td class="label">Ensembl ID</td>
<td>ENSG00000088038</td>
</tr>
<tr>
<td class="label">UniProt ID</td>
<td>Q99572</td>
</tr>
<tr>
<td class="label">EC50 for ATP</td>
<td>~100-300 μM (much higher than other P2X receptors)</td>
</tr>
<tr>
<td class="label">Agonists</td>
<td>ATP, BzATP (more potent), dibutyryl-cAMP</td>
</tr>
<tr>
<td class="label">Antagonists</td>
<td>Brilliant Blue G, KN-62, A-438079, AZD9056</td>
</tr>
<tr>
<td class="label">Allosteric modulators</td>
<td>Zinc (potentiator), Copper (inhibitor), pH effects</td>
</tr>
<tr>
<td class="label">Ion selectivity</td>
<td>Non-selective for cations, impermeable to anions</td>
</tr>
<tr>
<td class="label">Compound</td>
<td>Company</td>
</tr>
<tr>
<td class="label">AZD9056</td>
<td>AstraZeneca</td>
</tr>
<tr>
<td class="label">GSK-1482160</td>
<td>GSK</td>
</tr>
<tr>
<td class="label">A-438079</td>
<td>Pfizer</td>
</tr>
<tr>
<td class="label">JNJ-47965567</td>
<td>Janssen</td>
</tr>
<tr>
<td class="label">Year</td>
<td>Milestone</td>
</tr>
<tr>
<td class="label">1996</td>
<td>P2X7 cloning</td>
</tr>
<tr>
<td class="label">1999</td>
<td>Inflammasome link</td>
</tr>
<tr>
<td class="label">2004</td>
<td>P2X7 in AD</td>
</tr>
<tr>
<td class="label">2006</td>
<td>Knockout mice</td>
</tr>
<tr>
<td class="label">2012</td>
<td>Crystallography</td>
</tr>
<tr>
<td class="label">2015</td>
<td>Clinical trials</td>
</tr>
<tr>
<td class="label">2020</td>
<td>Brain-penetrant drugs</td>
</tr>
<tr>
<td class="label">Receptor</td>
<td>Expression</td>
</tr>
<tr>
<td class="label">P2X1</td>
<td>Platelets, smooth muscle</td>
</tr>
<tr>
<td class="label">P2X2</td>
<td>CNS, sensory neurons</td>
</tr>
<tr>
<td class="label">P2X3</td>
<td>Sensory neurons</td>
</tr>
<tr>
<td class="label">P2X4</td>
<td>CNS, immune</td>
</tr>
<tr>
<td class="label">P2X5</td>
<td>Immune, proliferation</td>
</tr>
<tr>
<td class="label">P2X6</td>
<td>CNS</td>
</tr>
<tr>
<td class="label">P2X7</td>
<td>Immune cells</td>
</tr>
<tr>
<td class="label">State</td>
<td>Trigger</td>
</tr>
<tr>
<td class="label">Closed</td>
<td>No ligand</td>
</tr>
<tr>
<td class="label">Open</td>
<td>ATP (brief)</td>
</tr>
<tr>
<td class="label">Extended open</td>
<td>ATP (prolonged)</td>
</tr>
<tr>
<td class="label">Desensitized</td>
<td>Sustained</td>
</tr>
<tr>
<td class="label">Compound</td>
<td>Target</td>
</tr>
<tr>
<td class="label">MCC950</td>
<td>NLRP3</td>
</tr>
<tr>
<td class="label">CRID3</td>
<td>NLRP3</td>
</tr>
<tr>
<td class="label">Tranilast</td>
<td>P2X7</td>
</tr>
<tr>
<td class="label">Calhex 231</td>
<td>P2X7</td>
</tr>
<tr>
<td class="label">Associated Diseases</td>
<td><a href="/wiki/als" style="color:#ef9a9a">ALS</a>, <a href="/wiki/aging" style="color:#ef9a9a">Aging</a>, <a href="/wiki/als" style="color:#ef9a9a">Als</a>, <a href="/wiki/alzheimer's-disease" style="color:#ef9a9a">Alzheimer's disease</a>, <a href="/wiki/anxiety" style="color:#ef9a9a">Anxiety</a></td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">200 edges</a></td>
</tr>
</table>

Introduction

The P2RX7 gene encodes the P2X7 purinergic receptor, a unique ligand-gated ion channel that plays a critical role in neuroinflammation and neurodegenerative disease pathogenesis. P2X7 is distinctive among purinergic receptors due to its ability to form a large pore upon prolonged activation, allowing the passage of molecules up to 900 Da. This receptor is predominantly expressed on microglia in the central nervous system (CNS), where it serves as a primary sensor of extracellular ATP released during tissue damage, cellular stress, or pathological processes. The activation of P2X7 triggers a cascade of inflammatory events, including NLRP3 inflammasome activation, caspase-1 activation, and the release of pro-inflammatory cytokines IL-1β and IL-18. [@mclarnon2006]

Gene Overview

Protein Structure and Pharmacology

Structural Architecture

The P2X7 receptor represents a unique class of ligand-gated ion channels with distinctive structural features:

• Trimeric assembly: P2X7 forms functional trimeric channels, each subunit containing two transmembrane domains (TM1 and TM2)
• Extracellular loop: The large extracellular domain contains ATP-binding sites and determines ligand specificity
• Cytoplasmic termini: Both N-terminal and C-terminal domains are cytoplasmically located and influence channel gating
• C-terminal proline-rich region: Unique among P2X receptors, the C-terminus contains a proline-rich domain that interacts with intracellular proteins

Pharmacological Properties

Molecular Mechanisms of Activation

Channel Gating Cascade

ATP binding initiates a cascade of events:

Key Signaling Pathways

• Potassium (K+) efflux (required signal)
• Pannexin-1 pore formation allowing ATP release
• ASC speck formation and caspase-1 activation

• IKK complex activation
• IκB degradation
• Nuclear translocation of p65/p50

• p38 MAPK: Cytokine production
• JNK: Apoptotic signaling
• ERK: Cell survival/differentiation

Normal Function in the Brain

Cellular Localization

• High expression: Microglia, particularly in hippocampus and basal ganglia
• Lower expression: Astrocytes and neurons
• Peripheral expression: Macrophages, lymphocytes, dendritic cells
• Regulation: Expression upregulated in response to neuronal injury

ATP Release Mechanisms

Understanding ATP release is crucial for targeting P2X7:

Calcium Signaling

P2X7 activation leads to significant calcium changes:

• Rapid calcium influx through the channel
• Activation of calcium-dependent kinases
• Calcineurin activation and dephosphorylation events
• Mitochondrial calcium overload in sustained activation

Cell Type-Specific Functions

Microglial P2X7

P2X7 plays a critical role in microglial phenotypic transitions:

• Surveying state: Low P2X7 expression, constant ATP sampling
• Activated state: P2X7 upregulation, pro-inflammatory cytokine release
• Dystrophic state: Age-related dysfunction, chronic inflammation

• IL-1β: Primary pro-inflammatory cytokine, processed by caspase-1
• IL-18: IFN-γ inducing factor, elevated in neurodegeneration
• TNF-α: Classic inflammatory mediator
• IL-6: Pleiotropic cytokine with both pro- and anti-inflammatory effects
• CXCL1/KC: Chemokine for neutrophil recruitment

Neuronal P2X7

• Present on subset of neurons
• Mediates necrotic cell death signaling
• Influences neurotransmitter release
• Affects synaptic plasticity

Astrocytic P2X7

• Regulates glutamate release
• Modulates astrocyte-neuron communication
• Involved in astrocyte migration
• Controls potassium homeostasis

Oligodendroglial P2X7

• Myelin maintenance functions
• White matter vulnerability in disease
• Precursor cell proliferation regulation

Disease Associations

Alzheimer's Disease

The P2X7 receptor is highly expressed on microglia and mediates ATP-induced cytokine release and inflammasome activation. Activation leads to IL-1β and IL-18 release, contributing to chronic neuroinflammation. P2RX7 polymorphisms are associated with AD risk, and blockade of P2X7 reduces pathology in mouse models.

Amyloid-Beta Interaction

• Aβ oligomers directly activate P2X7 on microglia
• P2X7 activation enhances Aβ uptake and processing
• Chronic IL-1β release accelerates tau pathology
• P2X7-mediated inflammation promotes Aβ generation

Tau Pathology Connection

• IL-1β-mediated tau kinase activation (GSK-3β, CDK5)
• Exacerbation of neuronal stress responses
• Microglial-mediated tau spread

Genetic Associations

• Gln460Arg (rs2230912): Associated with earlier onset
• Ala348Pro (rs208294): Modified disease progression
• Promoter variants: Altered microglial expression

Parkinson's Disease

The P2X7 receptor is highly expressed on microglia and mediates ATP-induced cytokine release and inflammasome activation. Elevated extracellular ATP in the substantia nigra drives microglial activation. P2X7-mediated microglial activation contributes to dopaminergic neuron loss. α-Synuclein aggregates can activate P2X7 receptors.

Dopaminergic Neuron Vulnerability

• Elevated extracellular ATP in substantia nigra
• Enhanced microglial activation around dopaminergic neurons
• Direct P2X7 expression on neurons affecting survival
• α-Synuclein-P2X7 interactions

MPTP/MPP+ Model Studies

• Reduced microglial activation
• Decreased dopaminergic neuron loss
• Improved motor function
• Reduced inflammasome activation

Amyotrophic Lateral Sclerosis

P2X7 activation on microglia promotes motor neuron toxicity:

• Upregulated expression in SOD1 mouse models
• Enhanced microglial toxicity to motor neurons
• Astrocytic P2X7 contributions
• Potential for therapeutic intervention

Multiple Sclerosis

P2X7 contributes to MS through:

• Demyelination-associated ATP release
• Inflammatory lesion formation
• T cell activation and infiltration
• Oligodendrocyte precursor damage

Brain Region Expression

Hippocampus

• Highest P2X7 expression in brain
• Critical for memory dysfunction in AD
• CA1 region particularly vulnerable
• Dentate gyrus neural stem cell effects

Substantia Nigra

• High microglial P2X7 density
• Explains PD vulnerability
• Dopaminergic neuron interaction
• Movement disorder connections

Cortex

• Layer-specific expression patterns
• Vulnerability in FTD
• Corticobasal degeneration links
• Language area involvement

P2X7 in Aging

Age-Related Changes

• Upregulated expression in aged brain
• Enhanced inflammasome activation
• Increased cytokine release
• Reduced cellular resilience

Brain Aging Interventions

• Anti-aging interventions may modulate P2X7
• Caloric restriction effects on P2X7
• Senolytic approaches affecting P2X7+ cells
• Exercise effects on P2X7 signaling

Therapeutic Targeting Strategies

Small Molecule Antagonists in Clinical Development

Challenges in Drug Development

• Blood-brain barrier penetration
• Species differences in receptor pharmacology
• Safety concerns with chronic immunosuppression
• Optimal dosing and timing of intervention

Approaches

• Small molecule inhibitors (preclinical)
• Monoclonal antibodies (preclinical)
• Gene therapy (research)

Novel Delivery Methods

• Liposomal formulations: Enhanced brain delivery
• Focused ultrasound: Temporary BBB opening
• Intranasal delivery: Direct nose-to-brain pathway
• Exosome loading: Cell-derived vesicles for delivery

Biomarker Potential

Fluid Biomarkers

• CSF P2X7: Detectable, elevated in AD/PD
• Soluble P2X7: Blood-based marker candidate
• IL-1β/IL-18 downstream: Reflects P2X7 activity

Imaging Biomarkers

• PET ligands: P2X7-targeted radiotracers in development
• Microglial imaging: TSPO as indirect P2X7 activity marker

Research Timeline

Comparative Analysis with Other P2X Receptors

Key Publications

Animal Models

Knockout Mice

• P2X7-/- mice show reduced neuroinflammation
• Improved memory in Aβ challenge paradigms
• Protection against MPTP-induced dopaminergic loss
• Reduced inflammasome activation

Transgenic Models

• Neuron-specific P2X7 overexpression
• Conditional knockout models
• Humanized P2X7 knock-in mice

Conclusion

P2RX7 encodes a critical receptor linking purinergic signaling to neuroinflammation across multiple neurodegenerative diseases. From basic receptor biology to clinical translation, P2X7 represents one of the most promising targets for disease-modifying therapies. Current clinical trials are testing brain-penetrant antagonists, and biomarker development may enable patient stratification. Understanding the complex cell-type-specific functions of P2X7 will be key to successful therapeutic translation.

Key Takeaways

Structural Biology

Crystal Structure Insights

The P2X7 receptor has been characterized through crystallography studies:

• ATP-binding site: Located in the extracellular domain
• Transmembrane pores: TM1 and TM2 form the ion channel
• C-terminal domain: Proline-rich region unique to P2X7
• Trimeric assembly: Three subunits form functional channels

Conformational States

Signaling Networks

Downstream Effectors

• NLRP3 recruitment
• ASC speck formation
• Pro-caspase-1 activation

• NF-κB activation
• AP-1 binding
• IRF7 pathway

• p38 MAPK
• JNK/SAPK
• ERK1/2

Cross-talk with Other Pathways

Therapeutic Development Pipeline

Preclinical Candidates

Clinical Pipeline Update

Phase II Trials:

• AZD9056: Completed for rheumatoid arthritis, repurposing for PD
• JNJ-54175446: Janssen's P2X7 antagonist, CNS trials planned

• BMS-986202: Bristol-Myers Squibb first-in-class
• GSK-3009788: GlaxoSmithKline program

Formulation Strategies

Biomarker Development

Patient Stratification

• P2RX7 genotyping: Identify responsive patients
• Expression markers: Peripheral monocyte P2X7
• Functional assays: ex vivo P2X7 responsiveness

Treatment Monitoring

• IL-1β reduction: Primary pharmacodynamic marker
• CSF P2X7: Target engagement biomarker
• Neuroimaging: Microglial activation markers

Regulatory Considerations

FDA/EMA Pathways

• Fast Track: P2X7 antagonists for ALS
• Breakthrough Therapy: Considerations for AD
• Orphan Drug: Rare neuroinflammatory conditions

Challenges

• Species differences: Translation from rodent models
• Chronic dosing: Safety monitoring requirements
• Biomarker qualification: Regulatory acceptance

Research Tools and Resources

Mouse Models

• P2X7 knockout: Global deletion
• Conditional knockout: Microglia-specific
• Humanized knock-in: Improved translation

Assay Platforms

• Flux assays: YOYO-1 dye uptake
• IL-1β release: ELISA quantification
• Calcium imaging: Fura-2 fluorescence

Future Perspectives

Emerging Areas

Unmet Needs

• Brain-penetrant P2X7 antagonists
• Biomarkers for patient selection
• Disease-modifying outcomes
• Combination therapy approaches

External Links

• [NCBI Gene: P2RX7](https://www.ncbi.nlm.nih.gov/gene/10278)
• [Ensembl: P2RX7](https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000088038)
• [UniProt: P2RX7](https://www.uniprot.org/uniprot/Q99572)
• [OMIM: P2RX7](https://www.omim.org/entry/601636)

See Also

• [Genes Index](/genes)
• [Neuroinflammation Pathway](/mechanisms/neuroinflammation-pathway)
• [Microglia](/cell-types/microglia)
• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Parkinson's Disease](/diseases/parkinsons-disease)
• [Amyotrophic Lateral Sclerosis](/diseases/amyotrophic-lateral-sclerosis)
• [NLRP3 Inflammasome](/mechanisms/nlrp3-inflammasome)
• [Alpha-Synuclein](/proteins/alpha-synuclein)
• [Amyloid-Beta](/proteins/amyloid-beta)

Pathway Diagram

The following diagram shows the key molecular relationships involving P2RX7 Gene discovered through SciDEX knowledge graph analysis: